Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples